CORRESP Filing
Coya Therapeutics, Inc.
Date: Aug. 18, 2025 · CIK: 0001835022 · Accession: 0001193125-25-182618
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289511
Letter
Re: Coya Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-289511) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:15 p.m., Eastern Time, on August 19, 2025, or as soon as practicable thereafter. Please call Hannah Pastore of Lowenstein Sandler LLP at (212) 419-5854 to confirm the effectiveness of the Registration Statement or with any questions.
Acceleration Request
August 18, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Very truly yours,
COYA THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request August 18, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Coya Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 (File No. 333-289511) Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission at 4:15 p.m., Eastern Time, on August 19, 2025, or as soon as practicable thereafter. Please call Hannah Pastore of Lowenstein Sandler LLP at (212) 419-5854 to confirm the effectiveness of the Registration Statement or with any questions. Very truly yours, COYA THERAPEUTICS, INC. By: /s/ Arun Swaminathan Name: Arun Swaminathan Title: Chief Executive Officer (Principal Executive Officer)